These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16984876)

  • 21. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
    Kanafani ZA; Perfect JR
    Clin Infect Dis; 2008 Jan; 46(1):120-8. PubMed ID: 18171227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardization of antifungal susceptibility testing and clinical relevance.
    Espinel-Ingroff A; Barchiesi F; Hazen KC; Martinez-Suarez JV; Scalise G
    Med Mycol; 1998; 36 Suppl 1():68-78. PubMed ID: 9988494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural products and antifungal drug discovery.
    Jacob MR; Walker LA
    Methods Mol Med; 2005; 118():83-109. PubMed ID: 15888937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antifungal susceptibility testing. Current state of technology, limitations, and standardization.
    Pfaller MA; Rinaldi MG
    Infect Dis Clin North Am; 1993 Jun; 7(2):435-44. PubMed ID: 8345178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility-testing in Aspergillus species.
    Lass-Flörl C; Perkhofer S
    Mycoses; 2008 Sep; 51(5):437-46. PubMed ID: 18422914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifungal susceptibility testing of Trichophyton rubrum by E-test.
    da Silva Barros ME; de Assis Santos D; Soares Hamdan J
    Arch Dermatol Res; 2007 May; 299(2):107-9. PubMed ID: 17333224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal susceptibility testing by flow cytometry: is it the future?
    Vale-Silva LA; Buchta V
    Mycoses; 2006 Jul; 49(4):261-73. PubMed ID: 16784439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility patterns of fungi associated with keratomycosis in horses of the northeastern United States: 68 cases (1987-2006).
    Ledbetter EC; Patten VH; Scarlett JM; Vermeylen FM
    J Am Vet Med Assoc; 2007 Oct; 231(7):1086-91. PubMed ID: 17916036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing the trailing endpoint observed in Candida albicans susceptibility testing using the CLSI procedure.
    Coenye T; De Vos M; Vandenbosch D; Nelis H
    Clin Microbiol Infect; 2008 May; 14(5):495-7. PubMed ID: 18341604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.
    Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing
    Clin Microbiol Infect; 2008 Oct; 14(10):982-4. PubMed ID: 18828858
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antifungigram: interpretation and choice of a technic].
    Vermorel O; Lebeau B; Claustre F; Grillot R
    Ann Biol Clin (Paris); 1989; 47(2):85-90. PubMed ID: 2735567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal susceptibility testing. New technology and clinical applications.
    Pfaller MA; Yu WL
    Infect Dis Clin North Am; 2001 Dec; 15(4):1227-61. PubMed ID: 11780273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolving role of antifungal susceptibility testing.
    Eschenauer GA; Carver PL
    Pharmacotherapy; 2013 May; 33(5):465-75. PubMed ID: 23553342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI).
    de Sousa ESO; Cortez ACA; de Souza Carvalho Melhem M; Frickmann H; de Souza JVB
    Braz J Microbiol; 2020 Dec; 51(4):1791-1800. PubMed ID: 32757139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of fungal susceptibility testing.
    Posteraro B; Sanguinetti M
    Future Microbiol; 2014; 9(8):947-67. PubMed ID: 25302953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
    Buchta V; Vejsova M; Vale-Silva LA
    Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.
    Albataineh MT; Sutton DA; Fothergill AW; Wiederhold NP
    Infect Dis Clin North Am; 2016 Mar; 30(1):13-35. PubMed ID: 26739605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New technique for testing antifungal agents.
    Oncology (Williston Park); 1990 Dec; 4(12):32. PubMed ID: 2149036
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.